跳至主要内容
临床试验/NCT02574741
NCT02574741已完成2 期

Augmenting Language Interventions in ASD: A Translational Approach (ACE Project 3)

University of California, Los Angeles1 个研究点 分布在 1 个国家目标入组 58 人开始时间: 2012年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
58
试验地点
1
主要终点
Number of words as assessed in a naturalistic language assessment

研究概览

简要总结

The study will consist of two main elements: the enrollment of 72 children aged 6-11 years with ASD and low language competency to receive a thrice-weekly one hour language intervention for 12 weeks; and, beginning at the same time, subjects will be equally randomized to receive either aripiprazole (Abilify) (flexibly dosed from 2-10 mg per day) or placebo for 12 weeks.

详细描述

Following screening for eligibility and baseline, study visits will be scheduled three times per week, with 2 sessions on-site at UCLA and one at home for parent training (allowing flexibility, as needed); study physician visits will occur once weekly for 6 weeks, then biweekly. Screening procedures may be completed in one or two visits, and measures obtained in other UCLA clinical or research setting may be used if assessments were done within one month of screening. Major outcome assessments will occur at baseline (Week 0), mid-point (Week 6), and final week (Week 12) by study personnel blind to visit number and drug group assignment; minor assessments will occur weekly along with study physician assessments occurring weekly for side effect and compliance checks. EEG will occur at or prior to baseline and at Visit 36 (Wk12). Arrangements will be made to transfer participants to standard clinical care following visit 36. Six months after visit 36, families will be seen for final follow-up assessments of language usage, social communication, overall functioning, health and ongoing treatment.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
5 Years 至 11 Years(Child)
性别
All
接受健康志愿者
否

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Aripiprazole

Active Comparator

Aripiprazole oral solution (1mg/mL) for 12 weeks. dosages range from 2-10mg per day.

干预措施: Behavioral Therapy (Behavioral)

Placebo

Active Comparator

50% will be randomized to placebo.

干预措施: Placebo (Drug)

Behavioral Intervention

Active Comparator

All subjects will receive behavioral therapy, in addition to either active study drug (aripiprazole) or placebo.

干预措施: Behavioral Therapy (Behavioral)

Behavioral Intervention

Active Comparator

All subjects will receive behavioral therapy, in addition to either active study drug (aripiprazole) or placebo.

干预措施: Placebo (Drug)

Placebo

Active Comparator

50% will be randomized to placebo.

干预措施: Behavioral Therapy (Behavioral)

Aripiprazole

Active Comparator

Aripiprazole oral solution (1mg/mL) for 12 weeks. dosages range from 2-10mg per day.

干预措施: Aripiprazole (Drug)

Behavioral Intervention

Active Comparator

All subjects will receive behavioral therapy, in addition to either active study drug (aripiprazole) or placebo.

干预措施: Aripiprazole (Drug)

结局指标

主要结局

Number of words as assessed in a naturalistic language assessment

时间窗: 12 weeks post baseline

word usage coded as assessed by a clinician-administered assessment

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

James McCracken

Director/Vice Chair

University of California, Los Angeles

研究点 (1)

Loading locations...

相似试验